MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Vaxart Inc

Затворен

0.32 -23.81

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.32

Максимум

0.32

Ключови измерители

By Trading Economics

Приходи

-3.6M

-16M

Продажби

5.7M

21M

Марж на печалбата

-74.684

Служители

105

EBITDA

-3.6M

-12M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+1775% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

5M

97M

Предишно отваряне

24.13

Предишно затваряне

0.32

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.07.2025 г., 15:46 ч. UTC

Значими двигатели на пазара

BitMine Shares Fall After Closing of $250 Million Private Placement

9.07.2025 г., 23:44 ч. UTC

Пазарно говорене

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

9.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9.07.2025 г., 22:59 ч. UTC

Пазарно говорене

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9.07.2025 г., 22:59 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

9.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.07.2025 г., 20:26 ч. UTC

Печалби

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9.07.2025 г., 19:18 ч. UTC

Пазарно говорене

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9.07.2025 г., 19:03 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9.07.2025 г., 18:31 ч. UTC

Пазарно говорене

Some Fed Officials Supported Considering July Cut -- Market Talk

9.07.2025 г., 17:07 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk -2-

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.07.2025 г., 16:14 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

9.07.2025 г., 16:14 ч. UTC

Пазарно говорене

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9.07.2025 г., 16:14 ч. UTC

Придобивния, сливания и поглъщания

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9.07.2025 г., 16:12 ч. UTC

Пазарно говорене

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9.07.2025 г., 16:08 ч. UTC

Пазарно говорене

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9.07.2025 г., 15:31 ч. UTC

Значими двигатели на пазара

BitMine Shares Fall After Closing of $250M Private Placement

9.07.2025 г., 15:31 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9.07.2025 г., 15:27 ч. UTC

Пазарно говорене

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9.07.2025 г., 14:36 ч. UTC

Придобивния, сливания и поглъщания

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9.07.2025 г., 14:31 ч. UTC

Придобивния, сливания и поглъщания

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9.07.2025 г., 14:26 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

9.07.2025 г., 14:26 ч. UTC

Пазарно говорене

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Ценова цел

By TipRanks

1775% нагоре

12-месечна прогноза

Среден 6 USD  1775%

Висок 8 USD

Нисък 4 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Vaxart Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.